Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

CER-001 Atherosclerosis Regression ACS Trial

ClinicalTrials.gov ID: NCT02484378

Public ClinicalTrials.gov record NCT02484378. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 4:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

CER-001 Atherosclerosis Regression ACS Trial; A Phase II Multi-Center, Double-Blind, Placebo-Controlled, Dose-Focusing Trial Of Cer-001 In Subjects With Acute Coronary Syndrome

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess the impact of ten intravenous infusions of 3 mg/kg CER 001 vs. placebo, given at weekly intervals for ten weeks, on atherosclerotic plaque volume as measured by coronary IVUS, when administered to subjects presenting with Acute Coronary Syndrome (ACS) with significant plaque volume.

Study identification

NCT ID
NCT02484378
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Cerenis Therapeutics, SA
Industry
Enrollment
301 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2015
Primary completion
Oct 31, 2016
Completion
Nov 30, 2016
Last update posted
Feb 10, 2019

2015 – 2016

United States locations

U.S. sites
13
U.S. states
11
U.S. cities
12
Facility City State ZIP Site status
Heart Center Research, LLC Huntsville Alabama 35801
VA San Diego Healthcare System San Diego California 92161
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Torrance California 90502
VA Eastern Colorado Health Care System Denver Colorado 80220
Jacksonville Center for Clinical Research Jacksonville Florida 32216
Cardiovascular Associates Research LLC Covington Louisiana 70433
Cardiac and Vascular Research Center of Northern Michigan Petoskey Michigan 49770
University of Missouri Health System Columbia Missouri 65212
Buffalo Heart Group LLP Buffalo New York 14215
Veterans Affairs WNY Healthcare System Buffalo New York 14215
Novant Health Heart and Vascular Institute Charlotte North Carolina 28204
South Oklahoma Heart Research, LLC Oklahoma City Oklahoma 73135
Dallas VA Medical Center Dallas Texas 75216

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02484378, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 10, 2019 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02484378 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →